Literature DB >> 18606872

MDMA (3,4-methylenedioxymethamphetamine)-mediated distortion of somatosensory signal transmission and neurotransmitter efflux in the ventral posterior medial thalamus.

M A Starr1, M E Page, B D Waterhouse.   

Abstract

MDMA (3,4-methylenedioxymethamphetamine, Ecstasy) is reported to enhance tactile sensory perception, an effect that is believed to contribute to its popularity as a recreational drug. To date, no literature exists that addresses the neurophysiological mechanisms underlying the effects of MDMA on somatosensation. However, MDMA interactions with the serotonin transporter protein (SERT) are well known. The rat trigeminal somatosensory system has been studied extensively and receives serotonergic afferents from the dorsal raphe nucleus. Given that these fibers express SERT, they should be vulnerable to MDMA-induced effects. We found that short-term low-dose MDMA administration (3 mg/kg i.p.) led to a significant increase in 5-hydroxytryptamine (5-HT) efflux in the ventral posterior medial (VPM) thalamus, the main relay along the lemniscal portion of the rodent trigeminal somatosensory pathway. We further evaluated the potential for MDMA to modulate whisker-evoked discharge (WED) of individual neurons in this region. After surgically implanting stainless steel 8-wire multichannel electrode bundles, we recorded spike train activity from single cells of halothane-anesthetized rats while mechanically activating the whisker pathway. We found that short-term low-dose MDMA (3 mg/kg i.p.) increased the spontaneous firing rate but reduced the magnitude and duration of WED in individual VPM thalamic neurons. It is noteworthy that the time course of drug action on neuronal firing patterns was generally consistent with increased 5-HT efflux as shown from our microdialysis studies. Based on these results, we propose the working hypothesis that MDMA may "distort" rather than enhance tactile experiences in humans, in part, by disrupting normal spike firing patterns through somatosensory thalamic relay circuits.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606872     DOI: 10.1124/jpet.108.139337

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats.

Authors:  Ratchanee Rodsiri; Clare Spicer; A Richard Green; Charles A Marsden; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

2.  Effects of repeated 3,4-methylenedioxymethamphetamine administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus.

Authors:  M A Starr; M E Page; B D Waterhouse
Journal:  J Pharmacol Exp Ther       Date:  2011-10-07       Impact factor: 4.030

3.  Mechanisms and environmental factors that underlying the intensification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced serotonin syndrome in rats.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan; H Daniel Adams; Zhiyuan Ma
Journal:  Psychopharmacology (Berl)       Date:  2014-10-11       Impact factor: 4.530

4.  Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Michael H Baumann; Richard B Rothman
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

5.  Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.

Authors:  Marta Concheiro; Michael H Baumann; Karl B Scheidweiler; Richard B Rothman; Gina F Marrone; Marilyn A Huestis
Journal:  Drug Metab Dispos       Date:  2013-10-18       Impact factor: 3.922

6.  Cellular profile of the dorsal raphe lateral wing sub-region: relationship to the lateral dorsal tegmental nucleus.

Authors:  Rani K Vasudeva; Barry D Waterhouse
Journal:  J Chem Neuroanat       Date:  2014-04-03       Impact factor: 3.052

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.